It’s a virtuous circle: New approval processes put in place by the European Medicines Agency are de-risking drug development, promoting investment in early-stage biotech and meeting unmet medical needs, says Paul Morton
At the fourth time of asking, the European Medicines Agency is recommending approval of Glybera, opening up a new era in the treatment of rare diseases, and unlocking the wider potential of gene therapy
The European Medicines Agency’s thumbs-down for rare disease treatment Glybera flies in the face of Commission policy. It’s also against the wishes of the European Parliament, and the impetus DG Sanco is putting into Orphan Drugs. Worse still, it’s bad for patients and kills innovation. By Nuala Moran.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that it has entered into an...
Biosimilars, e-health among areas targeted for collaboration in Science|Business panel in Washington